Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint

Trial Profile

Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izencitinib (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use

Most Recent Events

  • 27 Apr 2025 Status changed from recruiting to suspended. (Sponsor discontinued placebo. Unable to meet enrollment goals.)
  • 22 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Aug 2025.
  • 22 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top